Unknown

Dataset Information

0

Cost-effectiveness analysis of parenteral antimicrobials for acute melioidosis in Thailand.


ABSTRACT: Melioidosis is a common community-acquired infectious disease in northeast Thailand associated with overall mortality of approximately 40% in hospitalized patients, and over 70% in severe cases. Ceftazidime is recommended for parenteral treatment in patients with suspected melioidosis. Meropenem is increasingly used but evidence to support this is lacking.A decision tree was used to estimate the cost-effectiveness of treating non-severe and severe suspected acute melioidosis cases with either ceftazidime or meropenem.Empirical treatment with meropenem is likely to be cost-effective providing meropenem reduces mortality in severe cases by at least 9% and the proportion with subsequent culture-confirmed melioidosis is over 20%.In this context, treatment of severe cases with meropenem is likely to be cost-effective, while the evidence to support the use of meropenem in non-severe suspected melioidosis is not yet available.

SUBMITTER: Hantrakun V 

PROVIDER: S-EPMC4553702 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cost-effectiveness analysis of parenteral antimicrobials for acute melioidosis in Thailand.

Hantrakun Viriya V   Chierakul Wirongrong W   Chetchotisakd Ploenchan P   Anunnatsiri Siriluck S   Currie Bart J BJ   Peacock Sharon J SJ   Day Nicholas P J NP   Cheah Phaik Yeong PY   Limmathurotsakul Direk D   Lubell Yoel Y  

Transactions of the Royal Society of Tropical Medicine and Hygiene 20150513 6


<h4>Background</h4>Melioidosis is a common community-acquired infectious disease in northeast Thailand associated with overall mortality of approximately 40% in hospitalized patients, and over 70% in severe cases. Ceftazidime is recommended for parenteral treatment in patients with suspected melioidosis. Meropenem is increasingly used but evidence to support this is lacking.<h4>Methods</h4>A decision tree was used to estimate the cost-effectiveness of treating non-severe and severe suspected acu  ...[more]

Similar Datasets

| S-EPMC6610909 | biostudies-other
| S-EPMC4444096 | biostudies-literature
| S-EPMC7853568 | biostudies-literature
| S-EPMC5890745 | biostudies-literature
| S-EPMC5928800 | biostudies-literature
| S-EPMC2912810 | biostudies-other
| S-EPMC6917345 | biostudies-literature
| S-EPMC7607851 | biostudies-literature
| S-EPMC5633754 | biostudies-literature
| S-EPMC6055129 | biostudies-literature